Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome
- PMID: 12461473
Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome
Abstract
Background: To describe the frequency, in some European populations, of the World Health Organisation (WHO) defined metabolic syndrome and to compare the frequency of this syndrome with an alternative definition for non-diabetic subjects, called the insulin resistance syndrome proposed by the European Group for the Study of Insulin Resistance (EGIR).
Methods: Investigators of eight European studies contributed, according to a written protocol, the frequencies of abnormalities of these two syndromes, by sex and age class, as well as the overall frequencies of the syndromes and the average number of abnormalities: 8200 men and 9363 women were included.
Results: The frequency of both syndromes increased with age and was almost always higher in men than women for a given age. In non-diabetic subjects the frequency of the WHO syndrome varied between 7% and 36% for men 40 to 55 years; for women of the same age, between 5% and 22%. The EGIR syndrome was less frequent than the WHO syndrome (1% to 22% in men, 1% to 14% in women 40-55 years), and in men this was mainly due to the differing definitions of central obesity, as the WHO definition included overall obesity, BMI > or = 30 kg/m(2).
Conclusions: There is great variability in the frequency of the syndrome between different populations, due to the differing frequencies of the abnormalities and no doubt to the differing methodologies of measurement. Prospective studies and advances in the knowledge of physio-pathological mechanisms are required to determine the most appropriate and practical definition of the syndrome.
Similar articles
-
Analysis of criteria for metabolic syndrome in a population-based study of Japanese-Brazilians.Diabetes Obes Metab. 2005 Jul;7(4):352-9. doi: 10.1111/j.1463-1326.2004.00402.x. Diabetes Obes Metab. 2005. PMID: 15955121
-
National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study.Circulation. 2004 Sep 7;110(10):1251-7. doi: 10.1161/01.CIR.0000140762.04598.F9. Epub 2004 Aug 23. Circulation. 2004. PMID: 15326061
-
A comparison of the new international diabetes federation definition of metabolic syndrome to WHO and NCEP definitions in Chinese, European and South Asian origin adults.Ethn Dis. 2007 Summer;17(3):522-8. Ethn Dis. 2007. PMID: 17985508
-
Assessment of metabolic profile in a clinical setting.Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):589-95. doi: 10.1097/01.mco.0000241669.24923.8d. Curr Opin Clin Nutr Metab Care. 2006. PMID: 16912555 Review.
-
[Metabolic syndrome: definitions and epidemiological data].Rev Med Liege. 2003 Jul-Aug;58(7-8):479-84. Rev Med Liege. 2003. PMID: 14579611 Review. French.
Cited by
-
Relationship of sociodemographic and lifestyle factors and diet habits with metabolic syndrome (MetS) among three ethnic groups of the Malaysian population.PLoS One. 2020 Mar 19;15(3):e0224054. doi: 10.1371/journal.pone.0224054. eCollection 2020. PLoS One. 2020. PMID: 32191727 Free PMC article.
-
Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.Clin Biochem Rev. 2004 Feb;25(1):31-48. Clin Biochem Rev. 2004. PMID: 18516204 Free PMC article.
-
Assessment of the redox status in patients with metabolic syndrome and type 2 diabetes reveals great variations.Exp Ther Med. 2016 Mar;11(3):895-903. doi: 10.3892/etm.2016.2968. Epub 2016 Jan 5. Exp Ther Med. 2016. PMID: 26998009 Free PMC article.
-
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.Circulation. 2008 Jul 8;118(2):e20-8. doi: 10.1161/CIRCULATIONAHA.107.189623. Epub 2008 Jun 19. Circulation. 2008. PMID: 18566314 Free PMC article. No abstract available.
-
Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.Cancer Causes Control. 2009 Jul;20(5):653-61. doi: 10.1007/s10552-008-9278-7. Epub 2008 Dec 9. Cancer Causes Control. 2009. PMID: 19067190 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Medical